000148910 001__ 148910
000148910 005__ 20240229120021.0
000148910 0247_ $$2doi$$a10.3892/ol.2019.10901
000148910 0247_ $$2pmid$$apmid:31612061
000148910 0247_ $$2pmc$$apmc:PMC6781561
000148910 0247_ $$2ISSN$$a1792-1074
000148910 0247_ $$2ISSN$$a1792-1082
000148910 037__ $$aDKFZ-2020-00068
000148910 041__ $$aeng
000148910 082__ $$a610
000148910 1001_ $$aMay, Verena$$b0
000148910 245__ $$aChemovirotherapy for pancreatic cancer: Gemcitabine plus oncolytic measles vaccine virus.
000148910 260__ $$aAthens$$bSpandidos Publ.$$c2019
000148910 3367_ $$2DRIVER$$aarticle
000148910 3367_ $$2DataCite$$aOutput Types/Journal article
000148910 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1581516672_31382
000148910 3367_ $$2BibTeX$$aARTICLE
000148910 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000148910 3367_ $$00$$2EndNote$$aJournal Article
000148910 500__ $$aLA:L801
000148910 520__ $$aOncolytic virotherapy with vaccine viruses employs replicative vectors, which quite selectively infect tumor cells leading to massive virus replication followed by subsequent profound tumor cell death (oncolysis). Measles vaccine virus (MeV) has already shown great oncolytic activity against different types of cancers, including pancreatic cancer. Gemcitabine is a first line chemotherapeutic drug used for pancreatic cancer in palliative treatment plans. Furthermore, this drug can be used to induce senescence, a permanent cell cycle arrest, in tumor cells. In our preclinical work, three well-characterized immortalized human pancreatic cancer cell lines were used to investigate the combinatorial effect of MeV-based virotherapy together with the chemotherapeutic compound gemcitabine. Viability assays revealed that the combination of only small amounts of MeV together with subtherapeutic concentrations of gemcitabine resulted in a tumor cell mass reduction of >50%. To further investigate the replication of the oncolytic MeV vectors under these distinct combinatorial conditions, viral growth curves were generated. As a result, viral replication was found to be only slightly diminished in the presence of gemcitabine. As gemcitabine induces senescence, the effect of MeV on that phenomenon was explored using a senescence-associated β-galactosidase assay. Notably, gemcitabine-induced tumor cell senescence was not impaired by MeV. Accordingly, the chemovirotherapeutic combination of gemcitabine plus oncolytic MeV constitutes a novel therapeutic option for advanced pancreatic carcinoma that is characterized by the mutual improvement of the effectiveness of each therapeutic component.
000148910 536__ $$0G:(DE-HGF)POF3-899$$a899 - ohne Topic (POF3-899)$$cPOF3-899$$fPOF III$$x0
000148910 588__ $$aDataset connected to CrossRef, PubMed,
000148910 7001_ $$0P:(DE-HGF)0$$aBerchtold, Susanne$$b1
000148910 7001_ $$aBerger, Alexander$$b2
000148910 7001_ $$aVenturelli, Sascha$$b3
000148910 7001_ $$aBurkard, Markus$$b4
000148910 7001_ $$aLeischner, Christian$$b5
000148910 7001_ $$aMalek, Nisar P$$b6
000148910 7001_ $$0P:(DE-HGF)0$$aLauer, Ulrich M$$b7
000148910 773__ $$0PERI:(DE-600)2573196-8$$a10.3892/ol.2019.10901$$gVol. 18, no. 5$$n5$$p5534-5542$$tOncology letters$$v18$$x1792-1082$$y2019
000148910 909CO $$ooai:inrepo02.dkfz.de:148910$$pVDB
000148910 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000148910 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000148910 9131_ $$0G:(DE-HGF)POF3-899$$1G:(DE-HGF)POF3-890$$2G:(DE-HGF)POF3-800$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000148910 9141_ $$y2019
000148910 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000148910 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000148910 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000148910 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000148910 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bONCOL LETT : 2017
000148910 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000148910 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000148910 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000148910 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000148910 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000148910 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000148910 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000148910 9201_ $$0I:(DE-He78)L801-20160331$$kL801$$lDKTK Tübingen$$x0
000148910 980__ $$ajournal
000148910 980__ $$aVDB
000148910 980__ $$aI:(DE-He78)L801-20160331
000148910 980__ $$aUNRESTRICTED